Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation

Kazuhiro Imai Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan Abstract: Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Imai K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	air extruded jelly formulation alendronate sodium hydrate bisphosphonate elderly person oral jelly osteoporosis Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/7e6a5747cb3f491989a1a04e60621239
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e6a5747cb3f491989a1a04e60621239
record_format	dspace
spelling	oai:doaj.org-article:7e6a5747cb3f491989a1a04e606212392021-12-02T07:49:55ZAlendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation1178-1998https://doaj.org/article/7e6a5747cb3f491989a1a04e606212392013-06-01T00:00:00Zhttps://www.dovepress.com/alendronate-sodium-hydrate-oral-jelly-for-the-treatment-of-osteoporosi-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Kazuhiro Imai Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan Abstract: Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age, especially in postmenopausal women. Japan is one of the most rapidly aging societies worldwide. Japanese individuals over 65 years of age constituted 23.0% of the population in 2010 and 25.1% to 25.2% as of 2013. The estimated number of people with osteoporosis in Japan is currently 13 million. Bisphosphonates increase bone mineral density by inhibiting osteoclast-mediated bone resorption, thereby reducing the risk of fractures. Alendronate sodium hydrate (alendronate) is a bisphosphonate that potently inhibits bone resorption and is used to treat osteoporosis. Sufficient water is required to take an alendronate oral tablet; insufficient water could result in digestive system diseases, such as esophageal ulceration. Elderly patients with swallowing difficulty may choke on the tablet. Taking a tablet with oral jelly is a method to prevent digestive system disease and reduce the choking hazard. Once-weekly alendronate oral jelly was approved in 2012 by the Ministry of Health, Labour, and Welfare of Japan as the world's first drug for osteoporosis in a jelly formulation. It consists of a jelly portion and an air portion. The jelly formulation is smoothly discharged by pushing the air portion. Therefore, elderly patients with physical disabilities are able to easily take all of the jelly formulation from the package. In this review, this new formulation of alendronate sodium hydrate (oral jelly) is introduced and discussed in terms of osteoporosis treatment. This new formulation provides an alternative so that patients may select a method of dosing tailored to their preferences. Management of osteoporosis involves assessing fracture risk and preventing fractures. Higher adherence to the treatment of patients with osteoporosis and prevention of osteoporotic fractures are issues to be resolved. Keywords: air-extruded jelly formulation, alendronate sodium hydrate, bisphosphonate, elderly person, oral jelly, osteoporosisImai KDove Medical Pressarticleair extruded jelly formulationalendronate sodium hydratebisphosphonateelderly personoral jellyosteoporosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 681-688 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	air extruded jelly formulation alendronate sodium hydrate bisphosphonate elderly person oral jelly osteoporosis Geriatrics RC952-954.6
spellingShingle	air extruded jelly formulation alendronate sodium hydrate bisphosphonate elderly person oral jelly osteoporosis Geriatrics RC952-954.6 Imai K Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
description	Kazuhiro Imai Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan Abstract: Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age, especially in postmenopausal women. Japan is one of the most rapidly aging societies worldwide. Japanese individuals over 65 years of age constituted 23.0% of the population in 2010 and 25.1% to 25.2% as of 2013. The estimated number of people with osteoporosis in Japan is currently 13 million. Bisphosphonates increase bone mineral density by inhibiting osteoclast-mediated bone resorption, thereby reducing the risk of fractures. Alendronate sodium hydrate (alendronate) is a bisphosphonate that potently inhibits bone resorption and is used to treat osteoporosis. Sufficient water is required to take an alendronate oral tablet; insufficient water could result in digestive system diseases, such as esophageal ulceration. Elderly patients with swallowing difficulty may choke on the tablet. Taking a tablet with oral jelly is a method to prevent digestive system disease and reduce the choking hazard. Once-weekly alendronate oral jelly was approved in 2012 by the Ministry of Health, Labour, and Welfare of Japan as the world's first drug for osteoporosis in a jelly formulation. It consists of a jelly portion and an air portion. The jelly formulation is smoothly discharged by pushing the air portion. Therefore, elderly patients with physical disabilities are able to easily take all of the jelly formulation from the package. In this review, this new formulation of alendronate sodium hydrate (oral jelly) is introduced and discussed in terms of osteoporosis treatment. This new formulation provides an alternative so that patients may select a method of dosing tailored to their preferences. Management of osteoporosis involves assessing fracture risk and preventing fractures. Higher adherence to the treatment of patients with osteoporosis and prevention of osteoporotic fractures are issues to be resolved. Keywords: air-extruded jelly formulation, alendronate sodium hydrate, bisphosphonate, elderly person, oral jelly, osteoporosis
format	article
author	Imai K
author_facet	Imai K
author_sort	Imai K
title	Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
title_short	Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
title_full	Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
title_fullStr	Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
title_full_unstemmed	Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
title_sort	alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/7e6a5747cb3f491989a1a04e60621239
work_keys_str_mv	AT imaik alendronatesodiumhydrateoraljellyforthetreatmentofosteoporosisreviewofanoveleasytoswallowformulation
_version_	1718399165480828928

Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation

Ejemplares similares